Molecular Testing of Patients with GIST in Community Practice

Dr. Pollack emphasizes tissue-based next-generation sequencing as the gold standard for initial diagnosis and primary driver mutation identification. This testing remains absolutely essential at diagnosis to distinguish KIT-mutant from PDGFRA-mutant GIST and identify rare entities like SDH-deficient or NTRK-fusion tumors requiring different treatment approaches.

ctDNA serves as a useful adjunct in progressive disease settings, often capturing resistance mutation heterogeneity better than single-site biopsies. However, practical limitations include approximately 20% of patients lacking detectable ctDNA and incomplete resistance mutation detection in others.

For patients with inadequate tissue from initial biopsy (such as fine needle aspirates), the approach depends on clinical urgency and tumor accessibility. For rapidly progressing symptomatic patients, empiric imatinib treatment while sending ctDNA may be appropriate, with repeat biopsy if no response occurs.

The panel discusses biopsy approach preferences, generally favoring endoscopic over percutaneous biopsies for gastrointestinal primaries to minimize peritoneal seeding risk, though Dutch data suggest low actual seeding rates. Metastatic lesions, particularly liver metastases, can be biopsied safely for molecular profiling.

Dr. Heinrich notes that even limited tissue from fine needle aspirates can provide KIT mutation analysis through targeted PCR approaches, though comprehensive genomic profiling may require larger specimens. The key principle involves obtaining sufficient material for accurate diagnosis and treatment-guiding molecular characterization.